Cargando…
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
The implementation of hepatitis C (HCV) direct-acting antiviral drugs is prioritized in several populations in which its application provides the most immediate and impactful benefit. In this scenario, a precise knowledge of the situation of human immunodeficiency virus (HIV)/HCV chronic co-infectio...
Autores principales: | Rivero-Juarez, A., Gutierrez-Valencia, A., Castaño, M., Merino, D., Neukam, K., Ríos-Villegas, M. J., Lopez-Ruz, M. A., Jiménez-Aguilar, P., Marquez, M., Collado, A., Gomez-Vidal, A., Hernandez-Quero, J., Tellez, F., Fernandez-Fuertes, E., Rivero, A., López-Cortés, L. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607719/ https://www.ncbi.nlm.nih.gov/pubmed/26342330 http://dx.doi.org/10.1007/s10096-015-2476-9 |
Ejemplares similares
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
por: Rivero-Juarez, A., et al.
Publicado: (2016) -
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort
por: Neukam, Karin, et al.
Publicado: (2016) -
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015) -
Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012) -
What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis
por: Skaathun, Britt, et al.
Publicado: (2020)